# EDGAR Filing Document

**Accession Number:** 0001997296
**File Stem:** 0000950142-25-002133
**Filing Date:** 2025-8
**Character Count:** 9981
**Document Hash:** dcdd4a9744d11ff2b198bf69a41f6840
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950142-25-002133.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0000950142-25-002133

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medicus Pharma Ltd.
- **CENTRAL INDEX KEY:** 0001997296
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981778211
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94797
- **FILM NUMBER:** 251204313

**BUSINESS ADDRESS:**
- **STREET 1:** 300 CONSHOHOCKEN STATE RD.
- **STREET 2:** SUITE 200
- **CITY:** W. CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 610-540-7515

**MAIL ADDRESS:**
- **STREET 1:** 300 CONSHOHOCKEN STATE RD.
- **STREET 2:** SUITE 200
- **CITY:** W. CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Melani Kenneth R.
- **CENTRAL INDEX KEY:** 0002050471

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **STREET 1:** 100 KING ST W
- **STREET 2:** SUITE 3400
- **CITY:** TORONTO
- **STATE:** Z4
- **ZIP:** M5X 1A4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Medicus Pharma Ltd.

**Title of Class of Securities:** Common Shares, no par value

**CUSIP Number:** 58471K202

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Melani Kenneth R. | Names of Reporting Persons<br>Melani Kenneth R. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>3248741.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>3248741.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3248741.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3248741.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>18.2% | Percent of Class Represented by Amount in Row (9)<br>18.2% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Includes: (i) 409,411 common shares held by Dr. Kenneth Melani and (ii)  2,839,330 common shares held by Velocity Fund Partners, LP and entity controlled by Dr. Kenneth Melani. Dr. Kenneth Melani may be deemed the beneficial owner of securities held by Velocity Fund Partners, LP. Dr. Kenneth Melani disclaims beneficial ownership of such securities except to the extent of his direct ownership.

---

| 1. | Names of Reporting Persons<br>VELOCITY FUND PARTNERS, LP | Names of Reporting Persons<br>VELOCITY FUND PARTNERS, LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2839330.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2839330.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2839330.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2839330.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>15.9% | Percent of Class Represented by Amount in Row (9)<br>15.9% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

---

**Item 1(a). Name of Issuer:**
Medicus Pharma Ltd.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
300 CONSHOHOCKEN STATE RD., SUITE 200, W. CONSHOHOCKEN, PENNSYLVANIA, 19428.

**Item 2(a). Name of Person Filing:**
This statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"):
(i) Dr. Kenneth Melani; and
(ii) Velocity Fund Partners, LP

**Item 2(b). Address of Principal Business Office:**
The principal business address of each of the Reporting Persons is as follows:

1100 Stonegate Manor
Cheswick, PA 15024

**Item 2(c). Citizenship:**
See Row (4) of each Reporting Person's cover page.

**Item 2(d). Title of Class of Securities:**
Common Shares, no par value

**Item 2(e). CUSIP Number:**
58471K202

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Dr. Kenneth Melani directly owns 409,411 common shares of Medicus Pharma Ltd. (the "Company"). Velocity Fund Partners, LP an entity controlled by Dr. Kenneth Melani, directly owns  2,839,330 common shares. Dr. Kenneth Melani may be deemed the beneficial owner of the securities held by Velocity Fund Partners, LP. Dr. Kenneth Melani disclaims beneficial ownership of such securities except to the extent of this direct ownership.

**(b) Percent of class:**

See Row (11) of each Reporting Person's cover page. The percentages used herein are calculated based upon an aggregate of 17,816,266 common shares reported by the Company to be outstanding as of August 11, 2025, as reflected in the Company's Quarterly Report on Form 10-Q filed on August 11, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row (5) of each Reporting Person's cover Page

**(ii) Shared power to vote or to direct the vote:**

See Row (6) of each Reporting Person's cover Page

**(iii) Sole power to dispose or to direct the disposition of:**

See Row (7) of each Reporting Person's cover Page

**(iv) Shared power to dispose or to direct the disposition of:**

See Row (8) of each Reporting Person's cover Page

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Melani Kenneth R.**

**Date:** 08/12/2025

**By:** /s/ Kenneth Melani

**Name & Title:** Dr. Kenneth Melani

**VELOCITY FUND PARTNERS, LP**

**Date:** 08/12/2025

**By:** /s/ Kenneth Melani

**Name & Title:** Dr. Kenneth Melani, General Partner